Company intelligence / Profile preview

Pacific Marine Biotech

Torrington, Connecticut, United States

Ownership: Private
Employees: ~12
Development stage: Other

Overview

Pacific Marine Biotech is in preclinical/early-IND regulatory stages for Immune 12, a complex marine-derived biologic intended for glioblastoma and DIPG. Preclinical studies and limited early human experience are mentioned, but no fully published clinical results yet

Therapeutic areas: Oncology
Modalities: Complex biologicBiologic
Industry: Biotech

Partnerships

Seeking partners for FDA-regulated clinical trials with leading US healthcare institutions; no formally disclosed partnerships yet

Beyond the preview

Go deeper on Pacific Marine Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pacific Marine Biotech.

Explore the full profile